QAD Adaptive ERP review

QAD Adaptive ERP is the most direct answer to GxP compliance on this list, because QAD documents its life sciences coverage at the level of specific regulations. Its life sciences page says the platform supports medical device makers, pharmaceutical and biotech manufacturers, and CMOs and CDMOs with process maps built for FDA 21 CFR Part 11, Part 820 (QMSR) and Part 210/211. DSCSA, Unique Device Identification and country-specific serialization are native, lot and device genealogy runs from raw material to finished goods, and quality holds link straight to the affected lots and batches. Device history, design history, complaints and CAPA sit in QAD EQMS, which QAD positions as the record for FDA or notified-body audits. QAD also addresses the upgrade problem regulated plants worry about: its Champion Advantage program sequences modernization around the customer's compliance calendar to avoid a full revalidation cycle. The trade-offs are that QAD does not publish prices and that the quality depth assumes you run QAD EQMS too.

Who it is for

Medical device, pharma and contract manufacturers that need GxP controls built into the ERP

Price

See vendor pricing (USD check pending).

US price check pending. See the vendor pricing page.

Key features

• Process maps built for FDA 21 CFR Part 11, Part 820 (QMSR) and Part 210/211
• Native DSCSA and Unique Device Identification serialization support
• Lot and device genealogy from raw material to finished product
• Quality holds linked directly to affected lots and batches
• Device history, design history, complaints and CAPA in QAD EQMS

Strengths and weaknesses

• Strength: Covers medical devices, pharma, biotech and CMOs/CDMOs on one platform
• Strength: Serialization for DSCSA and UDI is native, so no separate serialization system is needed
• Strength: QAD says its Champion Advantage program sequences upgrades so they do not trigger a full revalidation cycle
• Weakness: No published USD price; pricing comes through a demo
• Weakness: Full quality coverage relies on QAD EQMS alongside the ERP
• Weakness: Built for manufacturers, so pure distributors or virtual biotechs may not use much of it

Key facts

• Regulations mapped: 21 CFR Part 11, Part 820 (QMSR), Part 210/211
• Serialization: Native DSCSA and UDI support
• Segments: Medical devices, pharma and biotech, CMOs/CDMOs
• Deployment: Cloud

Where it ranks

QAD Adaptive ERP is No. 1 in our Best ERP for Life Sciences verdict.